Morepen Laboratories Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹412Cr
- −5.9% YoY
- −3.1% QoQ
- Net profit
- ₹41Cr
- +17.1% YoY
- +272.7% QoQ
- Margin
- 7%
- −3 pp YoY
- +1 pp QoQ
Guidance rank: #77 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Morepen Laboratories Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Pharma Business (Total Revenue): EBITDA:
From Morepen Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Pharma Business (Total Revenue):
- Q2 FY26: Rs. 248 Crores
- Q2 FY25: Rs. 235 Crores
- YoY Growth: ~5.5%
- Pharma Business (Standalone Revenue):
- Q2 FY26: Rs. 374 Crores
- Q2 FY25: Rs. 395 Crores
- YoY Change: Slight decline (~5.3%)
- API Revenue:
- H1 FY26: Rs. 424 Crores
- H1 FY25: Rs. 455 Crores
- YoY Change: Decline (~6.8%)
- Medical Devices Revenue:
- Q2 FY26: Rs. 126 Crores
- Q2 FY25: Rs. 133 Crores
- YoY Change: Decline (~5.3%)
- Glucometer Sales:
- Q2 FY26 Revenue: Rs. 97 Crores (down from Rs. 103 Crores in Q2 FY25)
- Operating Profit (EBITDA):
- Consolidated Q2 FY26: Rs. 35 Crores (up from Rs. 29 Crores in Q1 FY26)
2 more points from Morepen Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Morepen Laboratories Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Morepen Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Morepen Laboratories Ltd — Quarterly revenue & net profit
Morepen Laboratories Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 412 | 438 | -5.9% | 425 | -3.1% |
| Operating profit (EBITDA) | 31 | 44 | -29.5% | 24 | +29.2% |
| Operating margin | 7% | 10% | -3 pp | 6% | +1 pp |
| Profit before tax | 46 | 46 | 0% | 16 | +187.5% |
| Net profit (PAT) | 41 | 35 | +17.1% | 11 | +272.7% |
| EPS (₹) | 0.75 | 0.64 | +17.2% | 0.20 | +275% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Morepen Laboratories Ltd Q2 FY26 results?
Pharma Business (Total Revenue): EBITDA:
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
